News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,672 Results
Type
Article (39808)
Company Profile (247)
Press Release (660617)
Multimedia
Podcasts (52)
Webinars (12)
Section
Business (204215)
Career Advice (2009)
Deals (35432)
Drug Delivery (95)
Drug Development (81059)
Employer Resources (172)
FDA (16192)
Job Trends (14865)
News (345276)
Policy (32561)
Tag
Academia (2555)
Accelerated approval (5)
Adcomms (21)
Allergies (86)
Alliances (49458)
ALS (96)
Alzheimer's disease (1388)
Antibody-drug conjugate (ADC) (133)
Approvals (16188)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (81)
Brain cancer (28)
Breast cancer (296)
Cancer (2350)
Cardiovascular disease (181)
Career advice (1678)
Career pathing (30)
CAR-T (162)
Cell therapy (448)
Cervical cancer (20)
Clinical research (66136)
Collaboration (866)
Company closure (2)
Compensation (574)
Complete response letters (19)
COVID-19 (2592)
CRISPR (43)
C-suite (252)
Cystic fibrosis (102)
Data (2381)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (279)
Diagnostics (6396)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (100)
Earnings (87285)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112780)
Executive appointments (750)
FDA (17593)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (784)
Gene editing (111)
Generative AI (20)
Gene therapy (322)
GLP-1 (725)
Government (4436)
Grass and pollen (4)
Guidances (174)
Healthcare (18825)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (126)
Indications (29)
Infectious disease (2737)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (99)
Interviews (312)
IPO (16534)
IRA (41)
Job creations (3633)
Job search strategy (1423)
Kidney cancer (10)
Labor market (43)
Layoffs (476)
Leadership (17)
Legal (7918)
Liver cancer (76)
Lung cancer (328)
Lymphoma (164)
Machine learning (9)
Management (58)
Manufacturing (331)
MASH (79)
Medical device (13390)
Medtech (13395)
Mergers & acquisitions (19485)
Metabolic disorders (720)
Multiple sclerosis (85)
NASH (16)
Neurodegenerative disease (98)
Neuropsychiatric disorders (28)
Neuroscience (1960)
NextGen: Class of 2025 (6515)
Non-profit (4482)
Now hiring (41)
Obesity (378)
Opinion (205)
Ovarian cancer (82)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (157)
Partnered (22)
Patents (250)
Patient recruitment (119)
Peanut (46)
People (57375)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20612)
Phase II (29135)
Phase III (21681)
Pipeline (1453)
Policy (149)
Postmarket research (2563)
Preclinical (8774)
Press Release (64)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (247)
Rare diseases (389)
Real estate (5908)
Recruiting (65)
Regulatory (22344)
Reports (50)
Research institute (2322)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (6)
RSV (42)
Schizophrenia (72)
Series A (135)
Series B (91)
Service/supplier (11)
Sickle cell disease (54)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3585)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (52)
The Weekly (31)
Vaccines (702)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (239)
Last 7 days (967)
Last 30 days (3525)
Last 365 days (32470)
2025 (12477)
2024 (35224)
2023 (40086)
2022 (51177)
2021 (55713)
2020 (54085)
2019 (46544)
2018 (35021)
2017 (32128)
2016 (31483)
2015 (37553)
2014 (31318)
2013 (26349)
2012 (28574)
2011 (29271)
2010 (27331)
Location
Africa (718)
Alabama (55)
Alaska (7)
Arizona (234)
Arkansas (13)
Asia (37904)
Australia (6199)
California (6575)
Canada (2103)
China (541)
Colorado (281)
Connecticut (285)
Delaware (160)
Europe (81485)
Florida (977)
Georgia (220)
Idaho (57)
Illinois (557)
India (25)
Indiana (324)
Iowa (11)
Japan (176)
Kansas (107)
Kentucky (24)
Louisiana (12)
Maine (63)
Maryland (933)
Massachusetts (4865)
Michigan (229)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (70)
New Hampshire (63)
New Jersey (1822)
New Mexico (28)
New York (1840)
North Carolina (1003)
North Dakota (8)
Northern California (2901)
Ohio (213)
Oklahoma (14)
Oregon (34)
Pennsylvania (1450)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (27)
South Dakota (1)
Southern California (2465)
Tennessee (108)
Texas (972)
United States (24501)
Utah (191)
Virginia (156)
Washington D.C. (65)
Washington State (576)
West Virginia (3)
Wisconsin (58)
700,672 Results for "grail inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GRAIL Reports First Quarter 2025 Financial Results
May 14, 2025
·
17 min read
Press Releases
GRAIL to Announce First Quarter 2025 Financial Results
April 29, 2025
·
1 min read
Biotech Beach
Illumina completes the divestiture of GRAIL
Illumina, Inc. announced the successful completion of the spin-off of GRAIL. This milestone follows the company’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company.
June 24, 2024
·
6 min read
Bio NC
GRAIL to Begin Trading on the Nasdaq Stock Exchange
GRAIL, Inc. announced its spin-off from Illumina is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of tomorrow, June 25, 2024.
June 24, 2024
·
9 min read
Biotech Beach
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
Illumina, Inc. announced that its Board of Directors has approved the spin-off of GRAIL.
June 3, 2024
·
6 min read
Press Releases
GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting
April 23, 2025
·
9 min read
Press Releases
GRAIL to Announce Fourth Quarter 2024 Financial Results
February 12, 2025
·
1 min read
Press Releases
GRAIL and Quest Diagnostics Provide GRAIL’s Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
February 13, 2025
·
9 min read
Press Releases
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
February 24, 2025
·
1 min read
Press Releases
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
February 21, 2025
·
18 min read
1 of 70,068
Next
